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Objective: To determine the optimum energy and beam arrangement for prostate intensity-
modulated radiation therapy (IMRT) delivery using an Elekta Beam ModulatorTM linear
accelerator, in order to inform decisions when commissioning IMRT for prostate cancer.
Methods: CMS XiO was used to create IMRT plans for a prostate patient. Arrangements with
3, 5, 7, 9 and 11 equally spaced ﬁelds, containing both a direct anterior and a direct posterior
beam were used, with both 6MV and 10MV photons. The effects of varying the maximum
number of iterations, leaf increment, number of intensity levels and minimum segment size
were investigated. Treatment plans were compared using isodose distributions, conformity
indices for targets and critical structures, target dose homogeneity, body dose and plan
complexity.
Results: Target dose conformity and homogeneity and sparing of critical structures improved
with an increasing number of beams, although any improvements were small for plans
containingmore than ﬁve ﬁelds. Set-ups containing a direct posterior ﬁeld provided superior
conformality around the rectum to anterior beam arrangements. Mean non-target dose and
total number of monitor units were higher with 6MV for all beam arrangements. The dose
distribution resulting from seven 6MV beams was considered clinically equivalent to that
with ﬁve 10MV beams.Conclusion: Methods have been developed to plan IMRT treatments using XiO for delivery
with a Beam ModulatorTM that fulﬁl demanding dose criteria, using many different set-ups.
This study suggests that 6MVphotons can produce prostate IMRT plans that are comparable
to those using 10MV. Work is ongoing to develop a complete class solution.
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Fig. 2 – Planning structures contoured in XiO. PTV, planning206 reports of practical oncology an
1. Introduction
With intensity-modulated radiation therapy (IMRT), the radi-
ation intensity within each ﬁeld is varied according to a
ﬂuence map calculated by a treatment planning system (TPS)
to provide the desired dose distribution, which is speciﬁed in
terms of dose and dose-volume constraints for targets and
organs at risk (OAR).1 The increased control over dose distri-
butions achieved with optimised intensity-modulated beams
can provide a signiﬁcant advantage when treating complex
geometries, for example where a target has a concave shape
arounda critical organ suchas theprostate around the rectum.
Studies show improved outcomes for localised prostate can-
cer following IMRT compared to three-dimensional conformal
radiation therapy (3DCRT).2–4 Dose escalation can signiﬁcantly
improve prostate-speciﬁc antigen (PSA) relapse-free survival
due to improved local tumour control.5 Radiation-induced
damage to surrounding critical structures becomes a limit-
ing factor in 3DCRT techniques, with the rectum being the
principal OAR. Intensity-modulation can improve dose con-
formality, conﬁning irradiation more closely to target volumes
to allow further increases in tumour dose while reducing the
normal tissue volumes irradiated.
IMRT is being commissioned in Leeds for the treat-
ment of prostate patients entered into the Conventional or
Hypofractionated High Dose Intensity Modulated Radiother-
apy for Prostate Cancer (CHHIP) trial,6 a study investigating
the hypothesis that shorter radiotherapy courses delivering
a higher dose per fraction may improve tumour control in
localised prostate cancer for a given level of radiation related
side effects. Prostate radiotherapy is currently delivered in
Leeds using 10MV photons from Beam ModulatorTM (BM) lin-
ear accelerators, and plans are generated using the XiO TPS
(Computerised Medical Systems Inc., St. Louis, USA). The BM
is an innovative type of treatment head from Elekta Oncology
Systems Ltd.,7 the physical and dosimetric characteristics of
which have been described previously.8 Fig. 1 shows the head
design. Themultileaf collimator (MLC) consists of 40 leaf pairs.
Each leaf projects a width of 4mm at the isocentre rather than
the conventional 1 cm. Themaximumbeamsize at the isocen-
tre is 16 cm×21 cm. The leaves are capable of interdigitation,
which is not possible in the standard Elekta MLC head.9 There
is no other movable collimation, e.g. backup diaphragms, in
the MLC head of a BM.
Fig. 1 – Schematic diagram of the Elekta Beam ModulatorTM
treatment head.target volume.
A ‘class solution’ is required for a new type of treatment,
to provide a starting point from which the majority of plans
can be created, making it possible to plan large numbers of
treatments with the minimum appropriate adjustments for
individual patients. This should specify a set of planning
parameters including photon energy, number and arrange-
ment of beams, and dose limits and penalties to be used by
the optimisation algorithm.
There is a range of literature on energy selection, and
selection of other IMRT parameters such as number of beams
and beam orientations for prostate treatment,10–21 some with
conﬂicting conclusions or recommendations. However, there
is currently no published literature regarding IMRT planning
using XiO for delivery with a BM, and a class solution must
be determined for this speciﬁc set-up. It is possible that previ-
ous observations may be speciﬁc to particular TPSs and linear
accelerator designs. The aim of this study is to determine the
optimum energy and beam conﬁguration for prostate IMRT
delivery using an Elekta BM by comparing achievable treat-
ment plans, in order to informdecisionswhen commissioning
IMRT for prostate cancer. The CHHIP protocol6 requires a
simultaneous boost technique delivering different doses to
three nested planning target volumes (PTV), while plans in
the reviewed literature involve at most two targets. In addi-
tion, results concerning the effects on dose distributions of
varying the number of ﬁelds and photon energy will add to
the knowledge base for this application.
2. Methods
2.1. Generation of treatment plans
Plans were created with XiO v4.33.02 for a prostate patient
with moderate risk of seminal vesicle involvement, using test
patient data from the CHHIP trial QA information.6 For this
patient group PTV1 is the prostate and seminal vesicles with
a 10mm isotropic margin (see Fig. 2). PTV2 and PTV3 are
deﬁned as prostate only plus a margin of 10mm and 5mm
respectively, with 5mm and 0mm towards the rectum. Mini-
mum and maximum doses to a structure are deﬁned as those
received by 99% and 1% of the volume respectively. The CHHIP
conventional 2Gy fractionation schedule was used, in which
the core high-dose region is prescribed 74Gy. The protocol
reports of practical oncology and radio
Table 1 – Normal tissue dose-volume constraints for the
CHHIP trial.6 Values in brackets are for guidance only.
Dose (Gy) for
2Gy/# schedule
Dose
(%)
Maximum
volume
Rectum 30 41 [80%]
40 54 [70%]
50 68 60%
60 81 50%
65 88 30%
70 95 15%
74 100 3%
Bladder 50 68 50%
60 81 25%
74 100 5%
Femoral heads 50 68 50%
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1Bowel 50 68 17 cm3
Urethral bulb 50 68 [50%]
60 81 [10%]
equiresminimumcoverage of PTV3with the 95% (70.3Gy) iso-
ose, with median dose in the range 99–101%. PTV2 requires
inimum coverage with 91% of 74Gy (67.3Gy), and PTV1 with
6% (56.2Gy). Dose-volume constraints are speciﬁed for the
ectum, bladder, femoral heads and bowel, with additional
uidance levels for the urethral bulb (Table 1).
The optimiser in XiO acts to minimise an overall cost
unction, which is the sum of individual objective functions
peciﬁed for each target and OAR to establish suitable dose
r dose-volume goals. Two parameters associated with these
bjectives can be varied in order to achieve a combination
f different goals. Increasing the weight of a particular dose
r dose-volume objective increases its relative importance
ith respect to other objectives. Power is used to increasehe magnitude of the penalty applied to voxels with doses
hat violate a structure’s objectives. Overlap priority is deter-
ined in XiO by the rank assigned to each structure, with
oxels lying inside more than one being governed by objec-
ig. 3 – Example IMRT prescription, for posterior ﬁve-ﬁeld arrang
enote the three transition volumes surrounding planning targe
.0 cm respectively. Weights range from 1 to 1000 and powers frotherapy 1 4 ( 2 0 1 0 ) 205–213 207
tives speciﬁed for the organ with the lowest number. PTV3
was therefore given the lowest rank,with increasing values for
PTV2 and PTV1. A suitable minimum dose limit was assigned
to each target to achieve the required coverage, and a maxi-
mum limit to constrain high dose. As found by others,10,11 it
was necessary to prescribe more stringent dose limits than
those required, since the optimisation algorithm cannot sat-
isfy all the demands placed on it, and segmentation degrades
plans.
In regions of high dose gradient, it can be useful to cre-
ate transition volumes to help transition the dose between
two areas with different prescriptions.22 Additional structures
were contoured around PTV1 as shown in Fig. 2, to aid the
transition fromhigh dosewithin the targets to low dose in sur-
rounding tissue, to make dose fall off more rapidly outside the
prostate. After investigating various combinations of margins,
PTV1 was grown in three dimensions by 0.3 cm, 0.6 cm and
1.0 cm. By requiring the optimisation algorithm to treat these
as OARs, each with a maximum dose limit equal to the mini-
mum dose of the structure immediately inside, conformity of
the 76% isodose to PTV1 was considerably improved.
Others who have developed class solutions for prostate
IMRT have found it necessary to deﬁne artiﬁcial structures
in order to achieve a conformal dose distribution.5,10 Fig. 2
illustrates all the structures that were used for planning in
this study. The rectum was divided into two separate struc-
tures to provide greater control over isodose shaping around
PTVs in the region of overlap. A maximum dose limit of 70Gy
for the part overlapping the targets (rectum+PTV1) pushes
areas of high dose within the targets away from the rectum.
A more stringent maximum dose (corresponding to the mini-
mum PTV1 dose) was applied to the part of the rectum outside
PTV1 (rectum−PTV1), togetherwith a dose-volume constraint
to control the rectumdose-volumehistogram (DVH). Similarly,
a maximum dose limit was applied to the part of the blad-
der inside the targets (bladder +PTV1), to reduce the bladder
volume receiving high dose. It was not necessary to specify
ement at 10MV. PTV1+0.3, PTV1+0.6 and PTV1+1.0
t volume 1, formed by adding margins of 0.3 cm, 0.6 cm and
m 2.0 to 5.0. OAR, organ at risk.
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constraints for the femoral heads or bowel in the prescription,
as doses were well within CHHIP limits for all plans.
An initial treatment plan was generated using ﬁve equally
spaced ﬁelds including a direct posterior beam, since several
centres use arrangements very similar to this,5,10,11 with 10MV
photons. The rank and dose and/or dose-volume objectives
for each target and OAR were varied, together with weights
and powers, to determine a combination that satisﬁed all the
CHHIP requirements. Fig. 3 shows the resulting prescription.
The beam arrangement and energy were then varied to gen-
erate a series of plans with 3, 5, 7, 9 and 11 equally spaced
ﬁelds, containing both a direct anterior and a direct posterior
beam, using both 6MV and 10MV photons. DVHs were used
to compare doses to targets and OARs with the criteria laid
out in the CHHIP protocol, to determine whether dose distri-
butions were acceptable. In most cases some constraints were
no longer met, and slight modiﬁcations to one or more dose
limits and/or penalties in the original prescription were usu-
ally necessary (optional CHHIP constraints were not always
met). Forward planning was also performed for comparison,
using a conventional 10MV four-beam box (FBB) technique
with an additional coned-down boost ﬁeld entering from each
direction.
The impact of a number of IMRT planning parameters on
dose distributions was investigated for a 10MV plan with a
ﬁve-beam posterior arrangement, to decide on suitable val-
ues to be used in all the plans for this study. A conformity
index was calculated for each PTV in order to compare plans
(deﬁned as the ratio of the total volume covered by 95% of
the prescribed dose to the target volume enclosed by that iso-
dose). Step increments (beamlet size in the direction of leaf
travel at the isocentre) in the allowed range of 0.3–2.0 cm
were investigated. To produce a deliverable plan, each beam is
divided into a number of smaller segments. The ideal inten-
sity maps are quantised into a user-deﬁned number of discrete
intensity levels. A minimum segment size is also speciﬁed; any
segments with an equivalent ﬁeld size below this value are
deleted. Plans resulting from segmentation with minimum
square segments across the allowed range of 0.0–3.0 cm, and
4–10 discrete intensity levels were compared. A maximum of
60 iterations in the optimisation was found to achieve the
objectives for all structures. Final dose calculations were per-
formed on a 0.2 cm×0.2 cm×0.2 cm grid.
2.2. Comparison of treatment plans
A number of ﬁgures of merit were used to quantitatively eval-
uate treatment plans using values measured from DVHs, in
addition to a visual assessment of isodose distributions. A
clinical oncologist who specialises in radiotherapy of urologi-
cal cancers viewed the dose distributions, to see whether the
ranking of plans using objective measures supported clinical
opinion.
Dose conformality to each PTV was assessed using a con-
formity index (CI), deﬁned for a reference isodose (RI), taken
to be the minimum dose covering the target, as:
CI = PTVRI
VRI
(1)iotherapy 1 4 ( 2 0 1 0 ) 205–213
where PTVRI and VRI denote the target volume and total tissue
volume receiving at least the reference dose. The conformal
index (COIN) deﬁned by Baltas et al.23 was used to incorporate
a measure of normal tissue avoidance. COIN values were cal-
culated for the minimum isodose covering each PTV using Eq.
(2):
COIN = PTVRI
PTV
× PTVRI
VRI
×
NCO∏
i=1
(
1 − VCO,RI,i
VCO,i
)
(2)
where NCO is the number of critical organs and VCO is critical
organ volume. COIN combines the quality of target coverage
with irradiation of both non-critical healthy tissues and crit-
ical organs in a single parameter, each component of which
tends towards 1 in the ideal case. Although this index was
originally proposed for brachytherapy, Feuvret et al.24 discuss
its application to external beam radiotherapy, where it can
be useful in high-precision techniques associated with a very
high dose gradient.
Another avoidance measure, a comprehensive quality
index (CQI) made up of individual quality indices (QI) for sur-
rounding critical structures based on their maximum dose
Dmax, used by Sheng et al.25 to compare techniques for treat-
ing sinus tumours,was applied to this comparison of 6MVand
10MV plans for N OARs:
CQI = 1
N
N∑
i=1
QIi =
1
N
N∑
i=1
D6max i
D10max i
(3)
An inhomogeneity index26 was used to compare dose uni-
formity within the targets:
∏
= Dmax − Dmin
Dmean
(4)
where Dmax, Dmin and Dmean are the maximum, minimum and
mean PTV dose.
Mean and maximum doses received by the whole body,
non-target tissue, and tissue more than 1 cm away from the
boundary of PTV1 were assessed for all plans. The total num-
bers of segments and monitor units (MU) were also compared,
as measures of plan complexity.
3. Results
3.1. IMRT planning parameters
Fig. 4 shows the variation of PTV conformity indiceswith IMRT
planning parameters. PTV1 dose conformity improved with
decreasing step size (Fig. 4a), with a smaller improvement
observed for PTV2. Step increments above 0.8 cm led to sig-
niﬁcant degradation of dose distributions. An increment of
0.3 cm provided only a very small improvement compared to
0.6 cm,while calculation time approximately doubled. For seg-
mented plans (with 5–10 intensity levels, minimum segment
size 1.6 cm), the total number of segments increased by 10–14
per centimetre decrease in leaf increment.
Dose conformity improved for all three PTVs with a smaller
minimum segment size, as shown in Fig. 4b. Conformity
reports of practical oncology and radiotherapy 1 4 ( 2 0 1 0 ) 205–213 209
Fig. 4 – Effect of varying IMRT planning parameters on planning target volume (PTV) conformity indices (deﬁned for each
PTV as the ratio of the total volume covered by 95% of the prescribed dose to the volume of the target enclosed by that
isodose). (a) Step increment (no segmentation). (b) Minimum segment size (step increment 1.0 cm, 10 discrete intensity
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alues before segmentation.
ndices for PTV2 and PTV3 began to diverge signiﬁcantly from
alues before segmentation for a minimum segment size
bove 1.6 cm. Target doses increasedwhen this parameterwas
ncreased above 1.6 cm. Although increasing the number of
iscrete intensity levels does not necessarily improve a dose
ig. 5 – Transverse dose distribution through the isocentre for ﬁv
0MV. (b) Posterior beam arrangement at 6MV. (c) Anterior beam
MV.cm, minimum segment size 1.6 cm). Dashed lines indicate
distribution, conformity generally improved with an increas-
ing number of levels (Fig. 4c), as did target dose homogeneity.
Dose conformity was considered inferior with fewer than six
or seven intensity levels. On average, the total number of seg-
ments increasedbyeight per centimetredecrease inminimum
e-ﬁeld IMRT plans. (a) Posterior beam arrangement at
arrangement at 10MV. (d) Anterior beam arrangement at
210 reports of practical oncology and radiotherapy 1 4 ( 2 0 1 0 ) 205–213
Fig. 6 – Examples of graphs comparing quantitative ﬁgures of merit between treatment plans. (a) Planning target volume
ludi
num(PTV) 1 conformity index (CI). (b) Conformal index (COIN) inc
inhomogeneity index. (d) Mean dose outside PTV1. (e) Total
segment size, and by six or seven with each additional inten-
sity level.
3.2. Comparison of treatment plans
3.2.1. Visual inspection of isodose distributions
Fig. 5 shows dose distributions in a typical slice for the ﬁve-
ﬁeld plans. In general as the number of beams increased,
isodoses conformed slightly more tightly to PTVs and high
dose was constrained in a smaller region around the prostate,
with improvements in target dose homogeneity. More accu-
rate shaping of the 56.2Gy (76%) isodose around PTV1 where
it overlaps the rectum, in terms of both target coverage
and rectum sparing, was achieved with a posterior beam
arrangement. For a given beam set-up, 10MV photons gave
comparable or better target dose homogeneity and conformityng all organs at risk (OAR) at dose level of PTV1. (c) PTV1
ber of monitor units. FBB, four-beam box.
than 6MV, with lower doses outside the prostate. High-dose
regions arose near the patient surface in plans using three
or ﬁve 6MV beams; Fig. 5b and d shows tissue in poste-
rior/anterior oblique beams receiving 44Gy.
3.2.2. Conformity
A clear advantage in both target volume CIs and COIN values
was demonstrated from using more than three beams, with
only small improvements observed as the number of ﬁelds
was increased above ﬁve. Fig. 6a and b illustrates this for the
minimum dose covering PTV1. For a given beam arrangement
there appears to be some advantage in the use of 10MV pho-
tons. At the dose level of PTV3, CI improved by an average of
7% compared to 6MV plans, and COIN values were higher, on
average by 10% when all OARs were considered. The FBB pro-
vided better dose conformity than three-ﬁeld plans, but IMRT
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ith ﬁve or more beams was superior in terms of CI and COIN
alues. QIs for the rectum and bladder lay within 1.5% of 1.0
n all cases. Considering maximum rectal doses, 10MV plans
ere slightly superior for ﬁve beam arrangements and 6MV
or four. For the bladder, eight beam arrangements were bet-
er for 10MV and only one for 6MV, although the bladder will
e full during treatment so most of this dose will actually be
elivered to urine. Combined CQIs for both OARs lay in the
ange 0.991–1.012; eight beam arrangements were better with
0MV and two with 6MV.
.2.3. Homogeneity
ose uniformity within the targets generally improved with
n increasing number of beams, as shown in Fig. 6c for PTV1.
or a posterior beam arrangement, homogeneity was found
o improve with up to seven or nine beams. In many cases
0MV plans showed better homogeneity than 6MV; within
TV3 10MV was superior in all cases except the three-beam
nterior arrangement. The FBB provided superior target dose
niformity compared to IMRT with even the highest numbers
f beams.
.2.4. Body dose
he mean dose to non-target tissues decreased substantially
hen ﬁve ormore ﬁeldswere used (Fig. 6d). It was consistently
igher in 6MV plans, by an average of 6% across the differ-
nt beam arrangements. The maximum dose in tissue more
han 1cm away from PTV1 showed a similar drop between
hree and ﬁve beams, with much smaller changes with addi-
ional ﬁelds. This was higher at 6MV for all but one beam
rrangement, with the difference between the two energies
ecreasing as the number of ﬁelds increased.
.2.5. Plan complexity
ach intensity-modulated beamused approximately the same
umber of segments. Therefore the total number of segments
equired to deliver a treatment increased in proportion with
he number of ﬁelds (on average by 11 or 12 with each addi-
ional beam). The total number of MU was higher for 6MV
hotons by up to 19% (Fig. 6e). A posterior beam arrange-
ent required more MU in all but one case. The range of
otal MU between plans decreased with an increasing num-
er of beams, converging to approximately 600. The forward
lan used only eight segments and required less than half the
verage number of MU for IMRT plans.
. Discussion
.1. IMRT planning parameters
he increase in number of segments (and therefore treatment
elivery time) with decreasing leaf increment or minimum
egment size, and increasing number of intensity levels, must
e weighed against the improvements in dose distributions.
step increment of 0.6 cm was chosen as a compromiseetween achieving desired dose distributions and limiting the
alculation time. This is in line with the recommendation of
u.27 A smaller leaf movement between segments increases
exibility in controlling individual beamlet intensities. A min-therapy 1 4 ( 2 0 1 0 ) 205–213 211
imum segment size of 1.6 cm was chosen, since no signiﬁcant
improvement was observed when smaller segments were per-
mitted, and dosimetry becomes less reliable for very small
ﬁelds. Eight intensity levels were used for this study, as this
was found to provide acceptable dose distributions in all cases.
4.2. Comparison of treatment plans
Both photon energies were able to provide adequate target
coverage and OAR sparing to satisfy the requirements of the
CHHIP protocol with all the beam arrangements investigated.
It was more difﬁcult to meet all the criteria when using fewer
ﬁelds, and this took many attempts with only three beams. It
was possible to achieve an acceptable dose distribution using
forward planning, although this irradiated more healthy tis-
sue than IMRTwith ﬁve ormore beams (shown by lower CI and
COIN values). The greater dose heterogeneity within targets
observed in IMRT plans compared to a FBB is generally recog-
nised as a trade-off for the increased OAR sparing achieved
with IMRT.10
Energy selection is critical for conventional external beam
radiotherapy. Lower photon energies have traditionally been
used to treat superﬁcial tumours, while higher energies pro-
vide greater penetration, enabling delivery of maximum dose
at depth without injuring shallow tissues when irradiating
deep-seated tumours. However, high energies introduce prob-
lems including increasingly diffuse beam boundaries due to
the greater lateral range of secondary electrons. Laughlin et
al.12 showed that the narrower penumbra of lower-energy
megavoltage X-ray beams results in a tighter dose distribu-
tion around a target, minimising irradiation of nearby OARs,
although regions near beam entry ports receive higher dose.
Observations that IMRT treatment planning depends much
less on energy optimisation, such as a study by Söderström
et al.13 suggesting that 6MV photons can provide effec-
tive treatments in most cases, have led to the manufacture
of IMRT-dedicated single intermediate energy linear accel-
erators, the advantages and disadvantages of which have
been discussed by Subramanian and Gibbons.14 Subramanian
argues that IMRT should be performed using 6–8MV photons,
for which dosimetry characteristics are better understood in
heterogeneous media and shielding is less expensive. Bene-
ﬁts of low energies include minimising total body dose from
head leakage, internal scatter and secondary neutrons. Advo-
cating the use of 10MV or above, Gibbons points out that
low-energy treatments deposit high dose in regions periph-
eral to the target, and generally require a more complex plan
containing a greater number of ﬁelds, beam segments and
MU. This increases treatment delivery times, integral dose and
irradiation of surrounding organs.
Prostate cancer has conventionally been treated using X-
rays at 10MV or above, but a lower energy may be sufﬁcient
with IMRT. A number of studies have compared 6MV prostate
IMRT with higher energies. Lu et al.15 found that 6MV beams
can achieve comparable dose distributions and DVHs to those
resulting from 15MV. De Boer et al.16 demonstrated no clinical
beneﬁt from the use of 18MV compared to 6MV, and Sun and
Ma17 showed that 6MV photons can produce equivalent plans
to 18MV even for exceptionally large patients.
d rad212 reports of practical oncology an
The clinical oncologist consulted in the present study
would be equally satisﬁed using either photon energy. High
entrance dose at 6MV gave rise to superﬁcial high-dose
regions in anterior/posterior oblique beams. This effect
decreased with an increasing number of beams, since fewer
MU entered through each. Although ﬁve beams provided an
acceptable dose distribution at 10MV, additional ﬁelds are
likely to be necessary if 6MV is to be used; with seven beams
the high-dose regions disappeared. This supports the obser-
vations of Pirzkall et al.18, who argue that IMRT does depend
on energy for deep-seated targets. While plans at 6MV, 10MV
and 18MVhad comparable dose distributions surrounding the
prostate, a signiﬁcant increase was observed in the volume
of tissue further than 1 cm from the target boundary receiv-
ing dose when using either low energy or few ﬁelds. However,
that study indicated that a minimum of nine ﬁelds is likely to
be necessary for 6MV prostate plans, while at 10MV six ﬁelds
should be acceptable.
Adverse skin reactions are therefore a concern for low-
energy treatment of deep-seated targets, particularly in large
patients. Thermoluminescencedosimetrymeasurementsper-
formed on the surface of a phantom19 have shown that
although skin doses during prostate IMRT treatments are
higher with 6MV than 18MV, they are signiﬁcantly reduced
for both energies compared with 3DCRT, and doses from 6MV
IMRT are substantially lower than 18MV 3DCRT. Chow et al.20
performed phantom measurements using metal oxide semi-
conductor ﬁeld effect transistor (MOSFET) detectors, which
showed that for a given number of ﬁelds surface doses are
higher at 6MV than 15MV, but the difference decreased from
approximately 30% to 5% as the number of IMRT beams was
increased from ﬁve to nine.
More MU are needed to deliver the required target dose
with 6MV photons due to their lower penetrability, resulting
in higher whole body doses. The FBB gave a signiﬁcantly lower
mean non-target dose than all the IMRT plans as it delivered
fewer MU, although the maximum dose was higher than IMRT
plansusingﬁve ormoreﬁelds due to large regions in the lateral
beams receiving up to 48Gy.
Differences in conformity and inhomogeneity indices
between 6MV and 10MV plans were not considered clini-
cally signiﬁcant. This supports previous studies that have
demonstrated no signiﬁcant variation in conformity or criti-
cal structure doses between prostate IMRT plans using photon
energies between 6MV and 18MV.16,18 In these IMRT stud-
ies, lower energies do not provide the improvement in dose
conformity observed with non-modulated beams.12 The mod-
ulation of beam intensities to achieve desired target and
OAR doses works independently of beam energy. The small
improvements in CI and COIN values seenwith 10MVphotons
compared to 6MV for a given beam arrangement do appear to
contradict a study in which conformal index values were the
same or slightly better for 6MV prostate IMRT plans compared
to 18MV.17 However, results will depend on the particular def-
initions adopted for indices, and none of the previous studies
used a BM where the different leaf size may affect conformity.To minimise the time required to plan and deliver treat-
ments and perform dosimetric veriﬁcation, it is desirable to
use the minimum number of beams that can achieve a satis-
factory treatment plan. Stein et al.21 found that the optimumiotherapy 1 4 ( 2 0 1 0 ) 205–213
number of equispaced coplanar intensity-modulated 15MV
photon beams to treat a typical prostate tumour increases
with prescription dose, ranging from 3–5 for 70Gy to 7–9 for
81Gy. Optimisation of beam orientations was found to signif-
icantly improve dose distributions compared to equiangular
arrangements only with ﬁve or fewer ﬁelds.
Increasing the number of beams provides greater con-
trol, and others have reported similar improvements in
conformality20 and target dose homogeneity.21 No signiﬁcant
advantagewasperceived from theuse ofmore thanﬁve beams
for 10MV or seven beams for 6MV, while three-ﬁeld plans
were inferior, in agreement with Mott et al.10 An arrange-
ment containing a direct posterior ﬁeld was preferred due
to the increased rectum sparing achieved through improved
conformity around the concave posterior PTV boundaries.
This supports the prediction of Stein et al.21, that intensity-
modulated beams entering from the direction of an OAR
partially enclosed by a target allow greater control over dose
distributions in this region. The variations in MU and body
dose support observations that energy becomes less impor-
tant as the number of IMRT beams increases, suggesting that
the value of using high energy to treat deep-seated targets
decreases with an increasing number of beams.18,20
4.3. Future work
The development of a class solution requires further inves-
tigation to determine an optimal set of inverse planning
parameters and prescription for the chosen beam arrange-
ment and photon energy. In order to perform a meaningful
comparison between treatment plans, the values used in this
study were not optimised for any particular set-up, so that dif-
ferences between prescriptions were minimised and all other
parameters could remain constant. This will need to be tested
on a number of additional patient datasets, in order to estab-
lish a robust class solution that provides a good starting point
in most cases. Dosimetric veriﬁcation measurements have
been performed using a Semiﬂex 0.125 cm3 ionisation cham-
ber and ﬁlms. These gave good agreement with XiO following
remodelling of the BM data speciﬁcally for the small ﬁelds
associated with IMRT.
5. Conclusion
IMRT treatments with a Beam ModulatorTM linear accelerator
have been successfully planned, and delivered to a phantom.
Planning methods have been developed with the XiO TPS to
generate acceptable plans fulﬁlling the demanding dose cri-
teria of the CHHIP trial, using many different set-ups. This
involved varying planning parameters in a systematic way
to determine appropriate values. A number of plan evalua-
tion parameters have been explored for comparing treatment
plans, and these have been related to clinical decisions.
6MV photons can achieve an equivalent dose distribution
to 10MV for prostate IMRT, provided a sufﬁcient number of
treatment ﬁelds is used to avoid high-dose regions near beam
entry points. This study suggests that seven beams are nec-
essary with 6MV while only ﬁve are required with 10MV. The
clinical oncologist who reviewed the plans considered that the
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osimetric differences observed between a seven-ﬁeld 6MV
lan and a ﬁve-ﬁeld 10MV plan for this patient would be
nlikely to be clinically signiﬁcant. A beam arrangement con-
aining a direct posterior ﬁeld provided superior conformality
round the rectum compared to an anterior arrangement.
lthough using 6MV slightly increases treatment calculation
nd delivery times and the number of QA measurements
equired, it will avoid the need to commission a second energy
or IMRT, and is thereforepreferred.Work is ongoing todevelop
complete class solution and carry out all necessary dosimet-
ic veriﬁcation.
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